France has confirmed a “rare risk” of atypical thrombosis linked to the AstraZeneca vaccine – Telam

AstraZeneca vaccine

The French Medicines Agency (ANSM) has confirmed the existence of a “rare” risk of atypical thrombosis linked to the AstraZeneca vaccine after having verified other cases in the country, including two fatal but recalling that the benefit / risk ratio of the vaccine is always favorable.

Nine cases of thrombosis, atypical due to their location (mainly cerebral, but also digestive) associated with thrombocytopenia or coagulation problems, were observed, six more compared to the previous week, reports the ASNM.

Among these cases, there are “two deaths” between March 12 and March 18, including a medical student who died several days after being vaccinated, according to the ANSA agency.

The cases occurred “on average 8.5 days after vaccination, in people with no particular history identified to date,” the agency said, adding that seven patients were under 55 and 2 were very old.

Over 1.4 million AstraZeneca vaccines supplied in France until March 18 5700 side effects were analyzed in drug monitoring centers. “Most were febrile symptoms, often severe in intensity, such as fever, headache and muscle pain.”